4HESS G, ROSS P, GAMM H, et al. Molecular analysis of the erythropoietin receptor system in patients with polycythemia vera[J]. Br J Haematol, 1994,88: 794- 802.
5BROUDY V C, LIN N, BRICE M, NAKAMOTO B, et al. Erythropoietin receptor characteristics on primary human erythroid cells[J]. Blood, 1991, 77:2583- 2590.
6SPIVAK J L. Polycythemia vera: myths, mechanisms, and management[J]. Blood,2002,100:4272 -4290.
7JAMES C,UGO V,CASADEVALL N. et al. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects [J].Trends Mol Med,2005,11:546-554.
8LEVINE R L, GILLILAND G D. Myeloproliferative disorders [J]. Blood, 2008,112 : 2190 - 2198.
9RAWLINGS J S, ROSIER K M, HARRISON D A. The JAK/STAT signaling pathway[J].J Cell Sci, 2004,117 : 1281 - 1283.
10JAMES C, UGO V, L E COUEDIC, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera[J]. Nature, 2005,434:1144 -1148.
